. . . " on a timely basis; regulatory delay in the approval of new therapeutics; limitations on cash flow for operations and investment due to debt service obligations; the inability to establish and maintain necessary product and process quality levels; the inability to realize the expected benefits of development, marketing, licensing and other alliances; competitive factors such as new membrane or chr" . . .